Co-Diagnostics, Inc. CoPrimer™ Platform Featured at PAG XXVII Conference
January 23 2019 - 06:30AM
Business Wire
Presentation coincided with launch of a
private-label CoPrimer product
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, patented platform for the
development of molecular diagnostic tests, announced today that
their CoPrimer™ platform was featured in presentations at the
International Plant and Genome conference (PAG XXVII) last week in
San Diego, California.
The public introduction of a novel, one-step SNP genotyping
methodology with scalable multiplex capability followed a joint
development project over the past year to test the performance of
CoPrimers in multiplexed reactions. It also coincided with a
private label CoPrimer product launch by a global leader in the
design and manufacture of sophisticated polymerase chain reaction
(PCR) reagents and other custom oligonucleotide-based tools for
applied markets. The patented structure of CoPrimers makes the
platform ideal for a wide array of PCR applications, including
infectious diseases, multiplexing of PCR reactions, SNP/SNV
detection, agricultural and food supply chain uses, liquid biopsy,
and next generation sequencing.
Mr. Dwight Egan, CEO of Co-Diagnostics, commented, “This product
launch marks the first private label product based on the CoPrimer
platform to be released on the market. We are excited for the
opportunities this affords us to expand the footprint of CoPrimers
to the manufacturer’s international client base. As adoption of
this technology helps the world become better acquainted with the
many features only allowed by CoPrimers, we anticipate that
Co-Diagnostics’ own brand and reputation as a developer and
licensor of unique, time- and cost-saving multiplex PCR technology
solutions will be enhanced.”
Marketing for the private labeled product includes its ability
to allow assay interchangeability, overcoming a common shortfall of
traditional multiplex PCR technologies, and to enable multiplex PCR
while maintaining workflow flexibility. This flexibility supports a
much broader range of applications including gene expression,
adventitious presence (AP) testing, copy number variation, and SNP
differentiation. The product can be designed with a range of
fluorescent dyes to fit most PCR detection instruments on the
market and allows customers to generate twice as much data per
reaction, which reduces overall cost of operations.
More information about the product, including contact
information for labs to learn how they can reduce cost and improve
efficiency, can be found here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking
statements in this release include statements regarding the (i) use
of funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190123005241/en/
Andrew BensonCo-Diagnostics Investor
Relations801-438-1036investors@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2023 to Mar 2024